Early Rebleeding Following Endoscopic Variceal Ligation Associated With Increased Mortality Risk
Time to rebleeding was a significant predictor of mortality risk following an endoscopic variceal ligation procedure.
Esophagus
Periodontal Disease, Tooth Loss Linked to Esophageal, Gastric Cancer
Periodontal disease and tooth loss, indicative of oral microbial dysbiosis, are associated with esophageal and gastric adenocarcinoma.
PPI Use and Dementia Development: Is There a Link?
PPIs are frequently used off-label and are easily accessible as over-the-counter products, contributing to the potential for adverse events or drug-drug interactions.
Improving Outcomes of Endoscopic Cricopharyngeal Myotomy in Zenker Diverticulum
A team of investigators assessed the ability of the intraprocedural functional lumen imaging probe to measure cricopharyngeal distensibility in patients undergoing endoscopy cricopharyngeal myotomy for Zenker diverticulum.
Routine Esophagram Following Peroral Endoscopic Myotomy does Not Reliably Identify Adverse Events
Post-procedural esophagram may be insufficient to diagnose serious adverse events in patients who underwent peroral endoscopic myotomy (POEM).
Sarcopenia a Prognostic Factor for Overall Survival in Men with Esophageal Carcinoma Treated With CRT
High sarcopenia levels appear to be negatively associated with overall survival in male patients with esophageal carcinoma treated with upfront chemoradiotherapy.
EsoFLIP-330 Safe for Treating Esophageal Motility Disorders
Use of a 30 mm hydrostatic balloon dilator (EsoFLIP-330) was safe in treating patients with esophageal motility disorders and was most effective in those with achalasia.
After Atrial Fibrillation, Oral Anticoagulants Increase Gastrointestinal Cancer Risk
Patients treated with non-vitamin K antagonist oral anticoagulants (NOACs) following atrial fibrillation were more likely to develop gastrointestinal bleeding and malignancies.
Opdivo Approved for Advanced Esophageal Squamous Cell Carcinoma
The FDA has approved Opdivo® (nivolumab; Bristol Myers Squibb) for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.
Clinical, Anatomic Improvements With Dupilumab in Eosinophilic Esophagitis Study
Dupilumab was associated with clinical and anatomic improvements in patients with eosinophilic esophagitis, according to results from a pivotal phase 3 study.
-
Loading...
-
Loading...
Next post in General Gastroenterology
